依洛尤单抗与心血管疾病患者的临床结局
FOURIER试验为随机、双盲、安慰剂对照研究,纳入27,564例接受他汀治疗且LDL胆固醇≥70 mg/dL的动脉粥样硬化性心血管疾病患者,随机接受依洛尤单抗(每2周140 mg或每月420 mg皮下注射)或匹配安慰剂。中位随访2.2年,48周时依洛尤单抗组LDL胆固醇较安慰剂组最小二乘均值降低59%(从基线中位数92 mg/dL降至30 mg/dL)。依洛尤单抗显著降低主要终点风险(9.8% vs 11.3%;HR 0.85;95%CI 0.79-0.92;P<0.001)和关键次要终点风险(5.9% vs 7.4%;HR 0.80;95%CI 0.73-0.88;P<0.001)。除注射部位反应外(依洛尤单抗2.1% vs 安慰剂1.6%),两组不良事件无显著差异。
要点
- 依洛尤单抗每2周140 mg或每月420 mg皮下注射,48周时LDL胆固醇较安慰剂组降低59%(从92 mg/dL降至30 mg/dL)。
- 主要终点(心血管死亡、心梗、卒中、不稳定心绞痛住院或冠脉血运重建)依洛尤单抗组9.8% vs 安慰剂组11.3%,HR 0.85(95%CI 0.79-0.92)。
- 关键次要终点(心血管死亡、心梗或卒中)依洛尤单抗组5.9% vs 安慰剂组7.4%,HR 0.80(95%CI 0.73-0.88)。
- 基线LDL胆固醇最低四分位亚组(中位数74 mg/dL)结果与总体一致。
- 注射部位反应依洛尤单抗组2.1% vs 安慰剂组1.6%,新发糖尿病和神经认知事件两组无显著差异。
适用人群与场景
- 动脉粥样硬化性心血管疾病患者,LDL胆固醇≥70 mg/dL(1.8 mmol/L),且正在接受他汀治疗。
诊断标准与关键阈值
- 主要终点为心血管死亡、心肌梗死、卒中、不稳定心绞痛住院或冠状动脉血运重建的复合终点。
- 关键次要终点为心血管死亡、心肌梗死或卒中的复合终点。
处置流程与药物剂量
- 依洛尤单抗140 mg每2周皮下注射或420 mg每月皮下注射,或匹配安慰剂。
研究设计与关键结果
- 随机、双盲、安慰剂对照试验,纳入27,564例动脉粥样硬化性心血管疾病患者,中位随访2.2年。
- 48周时LDL胆固醇最小二乘均值较安慰剂组降低59%,从基线中位数92 mg/dL降至30 mg/dL(P<0.001)。
- 主要终点依洛尤单抗组1344例(9.8%)vs 安慰剂组1563例(11.3%),HR 0.85(95%CI 0.79-0.92),P<0.001。
- 关键次要终点依洛尤单抗组816例(5.9%)vs 安慰剂组1013例(7.4%),HR 0.80(95%CI 0.73-0.88),P<0.001。
- 注射部位反应依洛尤单抗组2.1% vs 安慰剂组1.6%;新发糖尿病和神经认知事件两组无显著差异。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于接受他汀治疗且LDL胆固醇≥70 mg/dL的动脉粥样硬化性心血管疾病患者,依洛尤单抗可将LDL胆固醇降至中位数30 mg/dL并降低心血管事件风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain.
METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy. Patients were randomly assigned to receive evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The median duration of follow-up was 2.2 years.
RESULTS: At 48 weeks, the least-squares mean percentage reduction in LDL cholesterol levels with evolocumab, as compared with placebo, was 59%, from a median baseline value of 92 mg per deciliter (2.4 mmol per liter) to 30 mg per deciliter (0.78 mmol per liter) (P<0.001). Relative to placebo, evolocumab treatment significantly reduced the risk of the primary end point (1344 patients [9.8%] vs. 1563 patients [11.3%]; hazard ratio, 0.85; 95% confidence interval [CI], 0.79 to 0.92; P<0.001) and the key secondary end point (816 [5.9%] vs. 1013 [7.4%]; hazard ratio, 0.80; 95% CI, 0.73 to 0.88; P<0.001). The results were consistent across key subgroups, including the subgroup of patients in the lowest quartile for baseline LDL cholesterol levels (median, 74 mg per deciliter [1.9 mmol per liter]). There was no significant difference between the study groups with regard to adverse events (including new-onset diabetes and neurocognitive events), with the exception of injection-site reactions, which were more common with evolocumab (2.1% vs. 1.6%).
CONCLUSIONS: In our trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events. These findings show that patients with atherosclerotic cardiovascular disease benefit from lowering of LDL cholesterol levels below current targets. (Funded by Amgen; FOURIER ClinicalTrials.gov number, NCT01764633 .).
参考来源
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017. PMID: 28304224. doi:10.1056/NEJMoa1615664
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。